Rezvilutamide
Rezvilutamide is Hengrui's androgen receptor blocker, approved in China in 2022 for high-volume metastatic hormone-sensitive prostate cancer on the CHART trial, where it improved survival over bicalutamide.
Overview
Jiangsu Hengrui's rezvilutamide (SHR3680) received NMPA approval in June 2022 for high-volume metastatic hormone-sensitive prostate cancer with androgen deprivation, after the CHART phase 3 trial showed longer radiographic progression-free and overall survival than bicalutamide. Further phase 3 trials in non-metastatic and castration-resistant disease are registered. It is not approved outside China.
A second-generation antagonist of the androgen receptor, the class of enzalutamide, apalutamide and darolutamide, blocking androgen signalling in prostate cancer cells. Connects to Androgen receptor.
1.Rezvilutamide acts on Androgen receptor, the hormone receptor or the enzyme that makes the hormone.
- AmivantamabApproved
- CamizestrantApproved
- Comprehensive genomic profilingStandard of care
- Liquid biopsy (ctDNA)Standard of care
- LorlatinibApproved
- MRD / molecular residual disease testingEstablished
- ADC payload neutralisersPhase 1
- BGB-16673Phase 3
- Bispecific ADCPhase 3
- BRUIN CLL-321Positive
- CaDAnCe-304Recruiting
- CIRCULATE-Japan (GALAXY / VEGA / ALTAIR)Active
- A clone report from blood at every treatment cycle
- A fast route to the matched drug when it is licensed for another cancer
- A multi-cancer platform trial of adaptive (dose-holiday) therapy
- A national rapid research autopsy network for end-stage cancer
- A standard evolvability score for every tumour
- A standing platform trial that assigns treatment by how the tumour escaped
Background: ADC sequencing, Antigen escape (antigen loss, lineage switch), BCG-unresponsive, Castration-resistant prostate cancer (CRPC), Circulating tumour DNA (ctDNA). Also on OnCo: Resistance atlas · Lines of therapy.
Compare all products across the US, EU, UK, Japan, China and Australia →
Approvals
| Region | Year | Indication |
|---|---|---|
| CN | 2022 | High-volume metastatic hormone-sensitive prostate cancer with androgen deprivation therapy |
Trials
topTrials recruiting now
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Landmark trials
Latest papers
topQuery for this drug: (TITLE:"Rezvilutamide" OR ABSTRACT:"Rezvilutamide" OR TITLE:"SHR3680" OR ABSTRACT:"SHR3680") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Rezvilutamide, not a curated reading list.
Similar pages
not linked directly; found by shared links- TreatmentAZD9750
Shares Androgen receptor, Prostate cancer and the tag pipeline.
- TreatmentQLH12016
Shares Androgen receptor, Prostate cancer and the tag pipeline.
- TreatmentBMS-986365
Shares Androgen receptor, Prostate cancer and the tag pipeline.
- TreatmentHS-20093
Shares A Study of SHR3680, HS-20093 and SHR2554 in Subjects With Prostate Cancer, Prostate cancer and the tag pipeline.
- TreatmentEP0062
Shares Androgen receptor and the tag pipeline.
- TreatmentCAM2029 (octreotide subcutaneous depot)
Shares Endocrine therapy (SERMs, AIs, SERDs) and the tag pipeline.
- TreatmentAZD6621
Shares Prostate cancer and the tag pipeline.
- TreatmentJNJ-87189401
Shares Prostate cancer and the tag pipeline.